Compile Data Set for Download or QSAR
Report error Found 52 Enz. Inhib. hit(s) with all data for entry = 595
TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280730(US10030026, Compound C-12)
Affinity DataIC50: 23nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 24nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 24nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280724(US10030026, Compound C-3)
Affinity DataIC50: 26nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280729(US10030026, Compound C-11)
Affinity DataIC50: 28nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280732(US10030026, Compound C-16)
Affinity DataIC50: 30nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280732(US10030026, Compound C-16)
Affinity DataIC50: 30nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280732(US10030026, Compound C-16)
Affinity DataIC50: 30nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280726(US10030026, Compound C-5)
Affinity DataIC50: 32nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280726(US10030026, Compound C-5)
Affinity DataIC50: 32nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280727(US10030026, Compound C-6)
Affinity DataIC50: 34nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280737(US10030026, Compound C-127)
Affinity DataIC50: 38nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280737(US10030026, Compound C-127)
Affinity DataIC50: 38nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280737(US10030026, Compound C-127)
Affinity DataIC50: 38nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280728(US10030026, Compound C-7)
Affinity DataIC50: 43nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280733(US10030026, Compound C-17)
Affinity DataIC50: 48nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280725(US10030026, Compound C-4)
Affinity DataIC50: 52nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280735(US10030026, Compound C-24)
Affinity DataIC50: 52nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280734(US10030026, Compound C-18)
Affinity DataIC50: 59nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280734(US10030026, Compound C-18)
Affinity DataIC50: 59nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280734(US10030026, Compound C-18)
Affinity DataIC50: 59nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280738(US10030026, Compound C-142)
Affinity DataIC50: 89nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280736(US10030026, Compound C-33)
Affinity DataIC50: 89nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280731(US10030026, Compound C-15)
Affinity DataIC50: 93nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280736(US10030026, Compound C-33)
Affinity DataIC50: 110nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280723(N-(1-(2,2-difluoro-2-(pyridin-2-yl)ethyl)piperidin...)
Affinity DataIC50: 178nMT: 2°CAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 1.00E+3nMpH: 7.4Assay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280737(US10030026, Compound C-127)
Affinity DataIC50: 2.40E+3nMpH: 7.4Assay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280739(US10030026, Compound LX-1 | US10221182, Compound L...)
Affinity DataIC50: 4.50E+3nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280732(US10030026, Compound C-16)
Affinity DataIC50: 1.00E+4nMpH: 7.4Assay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280734(US10030026, Compound C-18)
Affinity DataIC50: 1.15E+4nMpH: 7.4Assay Description:Inhibitory activities of test compounds on 5 major isoforms of CYP P450 were evaluated by using pooled human liver microsome (HLM, purchased from BD ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280734(US10030026, Compound C-18)
Affinity DataIC50: 1.20E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280732(US10030026, Compound C-16)
Affinity DataIC50: 1.30E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280737(US10030026, Compound C-127)
Affinity DataIC50: 2.30E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280736(US10030026, Compound C-33)
Affinity DataIC50: 3.00E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280726(US10030026, Compound C-5)
Affinity DataIC50: 3.10E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280728(US10030026, Compound C-7)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280729(US10030026, Compound C-11)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280730(US10030026, Compound C-12)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280731(US10030026, Compound C-15)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280724(US10030026, Compound C-3)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280725(US10030026, Compound C-4)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280726(US10030026, Compound C-5)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280727(US10030026, Compound C-6)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280736(US10030026, Compound C-33)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280737(US10030026, Compound C-127)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280738(US10030026, Compound C-142)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280723(N-(1-(2,2-difluoro-2-(pyridin-2-yl)ethyl)piperidin...)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280732(US10030026, Compound C-16)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM280733(US10030026, Compound C-17)
Affinity DataIC50: 1.00E+7nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

Displayed 1 to 50 (of 52 total ) | Next | Last >>
Jump to: